Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.62 |
| ▸ | CBL | P22681 | 16/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152592 | 0.85 | CBLB (0.61) | CBLBCBL | |
| SCHEMBL24819991 | 0.85 | CBLB (0.61) | CBLBCBL | |
| SCHEMBL30152679 | 0.85 | CBLB (0.61) | CBLBCBL | |
| SCHEMBL24821819 | 0.85 | CBLB (0.61) | CBLBCBL | |
| SCHEMBL26481222 | 0.83 | CBLB (0.64) | CBLBCBL | |
| SCHEMBL26481225 | 0.80 | CBLB (0.66) | CBLBCBL | |
| SCHEMBL30963774 | 0.79 | CBLB (0.56) | CBLBCBL | |
| SCHEMBL26481226 | 0.79 | CBLB (0.64) | CBLBCBL | |
| SCHEMBL26481237 | 0.79 | CBLB (0.64) | CBLBCBL | |
| SCHEMBL30311255 | 0.78 | CBLB (0.78) | CBLBCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | CBLB 3/4885CBL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.